EKF Diagnostics Holdings Plc (EKF) - Product Pipeline Analysis, 2022 Update

Summary

EKF Diagnostics Holdings Plc (EKF Diagnostics) is an in vitro diagnostics company that designs, develops, manufactures, and markets point-of-care (POC) devices and tests; and central laboratory products. Its POC range includes hemoglobin analyzers, glucose analyzers and HbA1c analyzers that can be used for screening, monitoring and diagnosing patients, and conducting tests for common infectious diseases and pregnancy, while its central laboratory range includes various clinical reagents and centrifuges. Its products find application in blood banks, general surgeries, pharmacies, hospitals, diabetes clinics, laboratories, and sports medicine. The company sells its products through OEM partnerships with large distributors, and through agreements with local distributors in various countries. The company has offices in the UK, Germany, USA, Russia and China with a network of more than 200 distributors across various countries. EKF Diagnostics is headquartered in Penarth, Wales, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company EKF Diagnostics Holdings Plc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


EKF Diagnostics Holdings Plc Company Overview
EKF Diagnostics Holdings Plc Company Snapshot
EKF Diagnostics Holdings Plc Pipeline Products and Ongoing Clinical Trials Overview
EKF Diagnostics Holdings Plc – Pipeline Analysis Overview
Business Description
EKF Diagnostics Holdings Plc - Key Facts
EKF Diagnostics Holdings Plc - Major Products and Services
EKF Diagnostics Holdings Plc Pipeline Products by Development Stage
EKF Diagnostics Holdings Plc Ongoing Clinical Trials by Trial Status
EKF Diagnostics Holdings Plc Pipeline Products Overview
B-HB POC Analyser
B-HB POC Analyser Product Overview
BIOSEN HbA1c Instrument
BIOSEN HbA1c Instrument Product Overview
DiaSpect Tm
DiaSpect Tm Product Overview
FractalDx - Acute Transplant Rejection Diagnostic
FractalDx - Acute Transplant Rejection Diagnostic Product Overview
KidneyIntelX
KidneyIntelX Product Overview
KidneyIntelX Clinical Trial
Lactate Scout 4 - Clinic Use
Lactate Scout 4 - Clinic Use Product Overview
Point-Of-Care Test - Coagulation
Point-Of-Care Test - Coagulation Product Overview
Point-Of-Care Test - Vitamin D Test
Point-Of-Care Test - Vitamin D Test Product Overview
PointMan Assay - Breast Cancer
PointMan Assay - Breast Cancer Product Overview
PointMan Assay - Lung Cancer
PointMan Assay - Lung Cancer Product Overview
PointMan Assay - Skin Cancer
PointMan Assay - Skin Cancer Product Overview
PointMan PI3K DNA Enrichment Kit
PointMan PI3K DNA Enrichment Kit Product Overview
Quo-Lab - C-Reactive Protein
Quo-Lab - C-Reactive Protein Product Overview
RenaStat
RenaStat Product Overview
SensPoint
SensPoint Product Overview
Serum/Plasma Analyser
Serum/Plasma Analyser Product Overview
ß-Hydroxybutyrate LiquiColor Reagent
ß-Hydroxybutyrate LiquiColor Reagent Product Overview
Xtract Liquid Phase Extraction Device
Xtract Liquid Phase Extraction Device Product Overview
EKF Diagnostics Holdings Plc - Key Competitors
EKF Diagnostics Holdings Plc - Key Employees
EKF Diagnostics Holdings Plc - Key Employee Biographies
EKF Diagnostics Holdings Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
EKF Diagnostics Holdings Plc, Recent Developments
Nov 30, 2022: Renalytix reports financial results for first quarter of fiscal year 2023
Nov 22, 2022: Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30
Oct 31, 2022: Renalytix Reports Full Year Fiscal 2022 Results
Oct 31, 2022: Renalytix Reports Full Year Fiscal 2022 Results
Jun 30, 2022: Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
Jun 23, 2022: Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30
Jun 09, 2022: EKF Diagnostics Holdings : Launch of EKF Link
Apr 25, 2022: EKF Diagnostics Holdings announces Posting of Annual Report & Accounts &Notice of AGM
Mar 31, 2022: Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Mar 30, 2022: Renalytix announces Timothy Scannell appointed to the Board
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: EKF Diagnostics Holdings Plc Pipeline Products and Ongoing Clinical Trials Overview
Table 2: EKF Diagnostics Holdings Plc Pipeline Products by Equipment Type
Table 3: EKF Diagnostics Holdings Plc Pipeline Products by Indication
Table 4: EKF Diagnostics Holdings Plc, Key Facts
Table 5: EKF Diagnostics Holdings Plc, Major Products and Services
Table 6: EKF Diagnostics Holdings Plc Number of Pipeline Products by Development Stage
Table 7: EKF Diagnostics Holdings Plc Pipeline Products Summary by Development Stage
Table 8: EKF Diagnostics Holdings Plc Ongoing Clinical Trials by Trial Status
Table 9: EKF Diagnostics Holdings Plc Ongoing Clinical Trials Summary
Table 10: B-HB POC Analyser - Product Status
Table 11: B-HB POC Analyser - Product Description
Table 12: BIOSEN HbA1c Instrument - Product Status
Table 13: BIOSEN HbA1c Instrument - Product Description
Table 14: DiaSpect Tm - Product Status
Table 15: DiaSpect Tm - Product Description
Table 16: FractalDx - Acute Transplant Rejection Diagnostic - Product Status
Table 17: FractalDx - Acute Transplant Rejection Diagnostic - Product Description
Table 18: KidneyIntelX - Product Status
Table 19: KidneyIntelX - Product Description
Table 20: KidneyIntelX - A Clinical Validation Study of AI-enabled KidneyIntelX for Diagnosing Fast-Progressing Kidney Disease
Table 21: KidneyIntelX - A Prospective Decision Impact Clinical Utility Trial of KidneyIntelX in Patients with Type 2 Diabetes and Existing Chronic Kidney Disease
Table 22: KidneyIntelX - A Prospective Decision Impact Trial of KidneyIntelX in Patients with Type 2 Diabetes and Existing Chronic Kidney Disease
Table 23: KidneyIntelX - A Prospective Decision Impact Trial of KidneyIntelX in Patients with Type II Diabetes and Existing Chronic Kidney Disease
Table 24: KidneyIntelX - Multi-center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID)
Table 25: KidneyIntelX - Prospective Clinical Utility Study of Kidneyintelx AI-enabled for the Diagnosis of Kidney Disease
Table 26: KidneyIntelX - Real World Evidence Clinical Utility Study of KidneyIntelX in Patients with Type 2 Diabetes and Chronic Kidney Disease
Table 27: KidneyIntelX - Study to Evaluate the Uptake and Adherence to New Potassium-binding Agents in Patients with Chronic Kidney Disease and Hyperkalemia
Table 28: Lactate Scout 4 - Clinic Use - Product Status
Table 29: Lactate Scout 4 - Clinic Use - Product Description
Table 30: Point-Of-Care Test - Coagulation - Product Status
Table 31: Point-Of-Care Test - Coagulation - Product Description
Table 32: Point-Of-Care Test - Vitamin D Test - Product Status
Table 33: Point-Of-Care Test - Vitamin D Test - Product Description
Table 34: PointMan Assay - Breast Cancer - Product Status
Table 35: PointMan Assay - Breast Cancer - Product Description
Table 36: PointMan Assay - Lung Cancer - Product Status
Table 37: PointMan Assay - Lung Cancer - Product Description
Table 38: PointMan Assay - Skin Cancer - Product Status
Table 39: PointMan Assay - Skin Cancer - Product Description
Table 40: PointMan PI3K DNA Enrichment Kit - Product Status
Table 41: PointMan PI3K DNA Enrichment Kit - Product Description
Table 42: Quo-Lab - C-Reactive Protein - Product Status
Table 43: Quo-Lab - C-Reactive Protein - Product Description
Table 44: RenaStat - Product Status
Table 45: RenaStat - Product Description
Table 46: SensPoint - Product Status
Table 47: SensPoint - Product Description
Table 48: Serum/Plasma Analyser - Product Status
Table 49: Serum/Plasma Analyser - Product Description
Table 50: ß-Hydroxybutyrate LiquiColor Reagent - Product Status
Table 51: ß-Hydroxybutyrate LiquiColor Reagent - Product Description
Table 52: Xtract Liquid Phase Extraction Device - Product Status
Table 53: Xtract Liquid Phase Extraction Device - Product Description
Table 54: EKF Diagnostics Holdings Plc, Key Employees
Table 55: EKF Diagnostics Holdings Plc, Key Employee Biographies
Table 56: EKF Diagnostics Holdings Plc, Other Locations
Table 57: EKF Diagnostics Holdings Plc, Subsidiaries
Table 58: Glossary
List of Figures
Figure 1: EKF Diagnostics Holdings Plc Pipeline Products by Equipment Type
Figure 2: EKF Diagnostics Holdings Plc Pipeline Products by Development Stage
Figure 3: EKF Diagnostics Holdings Plc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings